1. Home
  2. BCPC vs GRFS Comparison

BCPC vs GRFS Comparison

Compare BCPC & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Balchem Corporation

BCPC

Balchem Corporation

HOLD

Current Price

$175.90

Market Cap

5.6B

Sector

Industrials

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.09

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCPC
GRFS
Founded
1967
1940
Country
United States
Spain
Employees
N/A
25247
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.5B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
BCPC
GRFS
Price
$175.90
$8.09
Analyst Decision
Buy
Hold
Analyst Count
2
2
Target Price
$176.00
$10.15
AVG Volume (30 Days)
179.3K
593.8K
Earning Date
04-30-2026
07-28-2022
Dividend Yield
0.55%
1.75%
EPS Growth
20.87
N/A
EPS
4.75
N/A
Revenue
$799,023,000.00
N/A
Revenue This Year
$8.47
$4.49
Revenue Next Year
$4.89
$6.42
P/E Ratio
$36.71
$18.67
Revenue Growth
13.56
N/A
52 Week Low
$139.17
$6.90
52 Week High
$183.90
$11.14

Technical Indicators

Market Signals
Indicator
BCPC
GRFS
Relative Strength Index (RSI) 58.45 44.92
Support Level $147.94 $7.64
Resistance Level $177.88 $8.88
Average True Range (ATR) 3.45 0.19
MACD 0.10 -0.03
Stochastic Oscillator 76.45 18.20

Price Performance

Historical Comparison
BCPC
GRFS

About BCPC Balchem Corporation

Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: